Description: Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Home Page: www.affymax.com
630 Fifth Avenue
New York,
NY
10020
United States
Phone:
650 812 8700
Officers
| Name | Title |
|---|---|
| Mr. Mark G. Thompson | CFO & Sec. |
| Mr. Jonathan M. Couchman | CEO, Pres & Director |
| Dr. Tracy J. Dunn Ph.D., J.D. | VP of Intellectual Property & Legal Affairs |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5584 |
| Price-to-Sales TTM: | 65.273 |
| IPO Date: | 2006-12-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |